SAB BIO to Showcase Innovative Diabetes Treatment Approach
![SAB BIO to Showcase Innovative Diabetes Treatment Approach](https://investorshangout.com/images/blog/ihnews-SAB%20BIO%20to%20Showcase%20Innovative%20Diabetes%20Treatment%20Approach.jpg)
SAB BIO to Showcase Innovative Diabetes Treatment Approach
MIAMI – SAB BIO (Nasdaq: SABS), a pioneering clinical-stage biopharmaceutical company, is at the forefront of developing cutting-edge immunotherapy for type 1 diabetes (T1D). This innovative treatment focuses on a human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset or slow the progression of this challenging condition.
Presentation at EASD Annual Meeting
On September 9, 2024, SAB BIO will present at the commemorable 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid. The session led by Alexandra Kropotova, MD, MBA, who serves as the Executive Vice President and Chief Medical Officer at SAB, will delve into a groundbreaking presentation titled “Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142.” This presentation aims to share critically important insights about their advanced immunotherapy approach.
Event Details
The EASD Annual Meeting, held in the Beijing Hall during the INNODIA EASD Symposium at 8:45 am, is one of the premier global events dedicated to diabetes research and treatment. It attracts thousands of delegates, including experts who come together to discuss the latest possibilities and progress within the realm of diabetes.
Understanding SAB-142
SAB-142 is a state-of-the-art therapeutic option designed to be a human analogue to rabbit anti-thymocyte globulin (ATG). This innovative treatment inverts traditional models by utilizing a low dosage of a human antibody, which presents fewer risks of severe immune reactions compared to its rabbit-derived counterpart. Clinical studies have highlighted that a modest single dose of rabbit ATG can effectively modulate the immune response, slowing the destructive progression of T1D by preserving the function of pancreatic beta cells.
Mechanism of Action
The pharmacological action of SAB-142 is aimed directly at immune cells responsible for attacking insulin-producing beta cells. By intervening at this critical juncture, the therapeutic promises to safeguard the body’s ability to produce insulin – a pivotal hormone for managing blood sugar levels. Unlike rabbit ATG, which can elicit serum sickness and immune responses such as the production of anti-drug antibodies, SAB-142's human-derived antibodies aim for safer and consistent treatment over time, enhancing patient compliance and therapy outcomes.
About SAB BIO
SAB BIO continues to lead advancements in the biopharmaceutical landscape, driven by its commitment to addressing serious unmet medical needs in immune and autoimmune disorders. By utilizing innovative genetic engineering techniques to develop their Transchromosomic (Tc) Bovine™ platform along with the DiversitAb™ drug development system, SAB BIO is uniquely positioned to produce a wide array of multi-targeted, high-potency immunoglobulins (IgGs). This innovative production model negates the historical dependency on human donors or convalescent plasma, heralding a new era of treatment possibilities for conditions like T1D.
Contacts
For media inquiries, please reach out to: Media Relations:
khollon@sab.bio
For investor relations, please contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What is SAB-142?
SAB-142 is a human immunotherapy targeted at preserving pancreatic beta cells to aid in delaying the progression of type 1 diabetes.
When will SAB BIO present at the EASD Annual Meeting?
SAB BIO will present on September 9, 2024, during the INNODIA EASD Symposium in Madrid.
Who is leading the presentation at EASD?
The presentation will be led by Dr. Alexandra Kropotova, Executive Vice President and Chief Medical Officer of SAB BIO.
How does SAB-142 differ from rabbit ATG?
SAB-142, being human-derived, reduces the risk of allergic reactions and promotes safer re-dosing compared to rabbit ATG, which can induce severe immune reactions.
How is SAB BIO addressing treatment for T1D?
SAB BIO is innovating treatments that leverage advanced technologies to target and preserve insulin-producing cells, fundamentally changing the management of type 1 diabetes.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Cadar Appoints Ralph Simons as CEO to Lead Fine Jewelry Brand
- Acer Unveils Swift Go 14 AI and Swift 14 AI Laptops Boosting Productivity
- Flexential's Innovative Growth Strategies Set for 2024 Success
- Market Volatility: Recession Fears Impact Investor Confidence
- Acer Unveils TravelMate P6 14 AI: A Game Changer in Laptops
- Saudi Arabia's Stock Market Overview: Tadawul Performance Insights
- Ongoing Ozempic Shortages Impacting Europe into Q4 2024
- Stocks Remain Resilient Amid Market Volatility: Insights
- SSI Raises $1 Billion to Develop Advanced AI Safety Solutions
- Global Market Index Sees Declining Returns for Investors
- Catchlight Launches Beta for Innovative Lead Routing Model
- Montway Auto Transport Celebrated as 2024 MOTOR Top 20 Winner
- GOOD GOOD Launches Innovative No Added Sugar Vegan Lemon Curd
- Solid Waste Management Market Expected to Hit $440 Billion by 2032
- Automated Liquid Handling Technologies Set for Major Growth
- The Dermatology Specialists Launch 50th Location with Free Screenings
- Remitly to Showcase Innovations at Upcoming Conference
- GridGain to Showcase Real-Time Data Innovations at Conferences
- Innovative FlashBang System Launch by Deep Sentinel for Businesses
- Educating Investors on 721 Exchange UPREIT Strategies
- ORBIS Production Recognized as Top Video Production Company
- Latin America Mining Equipment Market Set to Reach $10B by 2034
- COVID-19 Therapeutics Market Expected to Surpass $16 Billion
- Battery Coating Market Forecast: Growth to USD 1130 Million
- Ceramic Tiles Market Expected to Reach USD 420.65 Billion
Recent Articles
- Service World Expo 2024: Key Insights and Exciting Trends
- Wells Fargo Expands 'Signature Picks' with Microsoft and Adobe
- Nasdaq 100 Faces Pressure from Nvidia's Market Impact
- Healthcare Finance Solutions Market Expected to Reach $270.62 Billion
- Providence Treatment Expands Services as Dual Diagnosis Provider
- Satellite Communication Market Set to Reach USD 188.94 Billion
- Generative AI in Cybersecurity Market Set to Hit USD 5.96 Billion
- Odysight.ai Secures $10M Order for UAV Predictive Maintenance
- Vivid Seats Partners with I Am Athlete for Media Breakthrough
- American Rare Earths Accelerates Halleck Creek Development Plans
- PetSmart Announces Conference Call for Q2 2024 Financial Results
- Uruguay's Tender Offer Results and Bond Purchasing Details
- Join Bybit's $200K TON Tournament: Largest Web3 Airdrop
- Aya Gold & Silver Unveils Encouraging Drill Results
- Whitestone REIT Announces Q4 2024 Dividend Details
- Dollar Tree Faces Challenges with Q2 Results and Outlook
- Analyzing August's Underperforming Stocks: Opportunities Ahead
- Pantalones Organic Tequila Expands Nationally with Quality
- Escalade, Incorporated Celebrates 51 Years on Nasdaq Exchange
- Way.com Teams Up with Sea Air FCU for Affordable Auto Loans
- M&G Shares Decline as Company Announces Strategic Changes
- Airtel Africa's Stock Takes Hit After J.P. Morgan Downgrade
- New Era of Easy Money: Federal Reserve's Rate Cut Agenda
- Body Mist Market Set to Achieve USD 12.6 Billion by 2033
- Eurotech Unveils Generative AI Servers Optimized for NVIDIA AI